1. Pink Sheet
  2. >>Geography
  3. >>Asia
  4. >>Japan

Japan Lays Out New Antibiotics Plan As It Addresses Resistance Issues

Key Goals For 2027

 
• By Lisa Takagi

A new five-year strategic plan to counter antimicrobial resistance includes concrete new goals to reduce rates of resistance to specific drugs and support the development of new products.

Japan has already launched several counter-AMR measures
Japan has tightened several KPIs for AMR prevention • Source: Shutterstock

The Japanese government has officially approved a new five-year plan for counter-antimicrobial resistance (AMR) activities that will run from 2023 to 2027 and brings with it several new key performance indicators (KPIs) for the use of antibiotics.

Japan has already launched an incentive project for the R&D and marketing of safe and effective antibiotics as part of its AMR measures, and ahead of the its hosting of the G7 Summit in Hiroshima and preceding G7 Health Ministers’ Meeting in Nagasaki in May has been promoting general initiatives to tackle infectious diseases

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

Japan Looks To Build Domestic Capacity In New Modalities

 
• By Lisa Takagi

Japan's trade ministry is providing new support to build domestic capacity for new modalities including cell and gene therapies, as part of wider efforts to support the national bioventure ecosystem.

Japan Identifies Drugs ‘In Urgent Need’ Of Development

 
• By Lisa Takagi

Artesunate for malaria, TB drug pretomanid and omadacycline for pneumonia and skin infections are among the drugs identified by Japanese regulatory authorities in urgent need of domestic development.

Japan Pushes Generic Industry Reforms Via New Govt Fund

 
• By Lisa Takagi

Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.

Japan Expands Priority R&D List For Regular Vaccinations

 
• By Lisa Takagi

Japan adds four new pediatric vaccines, including for MMRV and norovirus, to a list of priority vaccines eligible for assistance in regulatory processing.

More from Asia

Pipeline To Product – What Is Driving Cell And Gene Therapy Progress In India?

 
• By Vibha Ravi

US-based Colossal Labs has claimed to bring back the dire wolf from extinction. While the science is not as dramatic in India yet, cell and gene therapies are making progress as treatments for cancer and other diseases. Pink Sheet takes a look at what is driving CGT success and growth.

Japan Identifies Drugs ‘In Urgent Need’ Of Development

 
• By Lisa Takagi

Artesunate for malaria, TB drug pretomanid and omadacycline for pneumonia and skin infections are among the drugs identified by Japanese regulatory authorities in urgent need of domestic development.

US Tariff Impact On Korea Dissected As Country Gears For Presidential Election

 
• By Jung Won Shin

Analysts expect a limited impact on South Korean pharma from US tariffs, even if imposed at a later date. Meanwhile, the early June domestic presidential election is set to determine the direction of policies in the sector.